3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW Le Roux, A Astrup, K Fujioka, F Greenway… - The Lancet, 2017 - thelancet.com
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
CW le Roux, A Astrup, K Fujioka, F Greenway, D Lau… - 2017 - agris.fao.org
Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose metabolism after
the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year …
the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW le Roux, A Astrup, K Fujioka, F Greenway… - The Lancet, 2017 - Elsevier
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW le Roux, A Astrup, K Fujioka, F Greenway… - The …, 2017 - research.sahmri.org.au
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW Le Roux, A Astrup, K Fujioka, F Greenway… - Lancet, 2017 - orbi.uliege.be
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
[PDF][PDF] 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW le Roux, A Astrup, K Fujioka, F Greenway… - 2017 - core.ac.uk
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW le Roux, A Astrup, K Fujioka, F Greenway… - THE LANCET, 2017 - cris.unibo.it
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
[引用][C] 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
CW le Roux, A Astrup, K Fujioka, F Greenway… - …, 2017 - espace.library.uq.edu.au
Background Liraglutide 3. 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
CW le Roux, A Astrup, K Fujioka… - Lancet (London …, 2017 - europepmc.org
Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
C Le Roux, A Astrup, K Fujioka, F Greenway, D Lau… - 2017 - digital.library.adelaide.edu.au
Background: Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …